PanDox: Targeted Doxorubicin in Pancreatic Tumours

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will combine focused ultrasound to generate heat, and a heat-sensitive chemotherapy drug (ThermoDox®), delivered into the blood of participants with non-resectable pancreatic cancer. We will compare this to standard delivery of chemotherapy - the drug Doxorubicin given into the blood without the addition of ultrasound. We aim to determine whether the novel approach to delivering chemotherapy with heating the tumour by focused ultrasound can enhance the amount of drug delivered to pancreatic tumours. This will be measured by analysing a biopsy sample of treated tumour.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oxford
• Collaborators: Celsion; National Institute for Health Research, United Kingdom; Oncology Clinical Trials Office
• Treatments: Doxorubicin

Criteria

Inclusion Criteria:

• Able to give informed consent prior to any screening procedures being performed and is able and willing to comply with the protocol and its requirements.

• Male or Female, aged 18 years or above.

• Prior histological confirmation of pancreatic adenocarcinoma

• Non-resectable or metastatic (stage IV)

• The primary pancreatic lesion measuring at least 1.5cm minimum diameter and amenable to EUS biopsy sampling

• ECOG performance status 0-1 (Appendix 1)

• Left ventricular ejection fraction (LVEF) ≥ 50% as determined by echocardiogram

• Willing to allow his or her General Practitioner and Consultant, if appropriate, to be notified of participation in the trial.

• Life expectancy of at least 3 months

• Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use highly effective contraception during the trial and for 6 months thereafter.

• Participant has clinically acceptable laboratory results during screening window:

Lab Test Value required Haemoglobin (Hb) (transfusion to achieve this allowed) ≥ 9g/dL Neutrophils ≥ 1.5 109/L Platelet count ≥ 100 109/L ALT ≤ 2.5 x ULN Alkaline phosphatase ≤ 5 x ULN Serum Bilirubin (stenting to achieve this allowed) ≤ 1.5 x ULN Creatinine Clearance (Calculated by Cockcroft-Gault criteria) ≥ 50ml/min INR <1.5 unless taking oral anticoagulant (this to be stopped at least 1 week prior to biopsy, at which point this INR limit will then apply)

Exclusion Criteria:

A patient will be ineligible for inclusion in this study if any of the following criteria apply:

• Significant renal or hepatic impairment.

• Unstable ischemic heart disease, cardiac dysrhythmias, coronary/peripheral artery bypass graft or cerebrovascular accident within 6 months prior to starting treatment

• Uncontrolled arterial hypertension despite medical treatment.

• Ongoing congestive heart failure or cardiac dysrhythmias of NCI CTCAE Grade ≥2 or uncontrolled atrial fibrillation.

• On-going significant infection (chest, urine, blood, intra-abdominal).

• Uncontrolled diabetes.

• Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.

• Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such procedure

• Previous targeted therapies to the pancreatic adenocarcinoma (including radiofrequency ablation or radiotherapy)

• History of other malignancy less than 3 years before the diagnosis of current cancer, EXCLUDING the following: Non-melanoma skin cancer, in situ carcinoma of the cervix treated surgically with curative intent, other malignant tumours that have been treated curatively and patient is deemed disease-free

• Endocrine therapy - patients with prostate cancer may continue to receive endocrine therapy to maintain castrate levels of androgens

• Known allergic reactions to any of the drugs or liposomal components or intravenous imaging agents used in this study

• Resting ECG with QTc >480msec at 2 or more time points within a 24h period (using Fredericia correction).

• Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that the investigator considers would make the patient a poor trial candidate, would impart excess risk associated with study participation or drug administration or could interfere with protocol compliance or the interpretation of trial results.

• Female participant who is pregnant, lactating or planning pregnancy during the course of the trial. However, those female patients who have a negative serum pregnancy test before enrolment and agree to use one highly effective form of contraception (oral, injected or implanted hormonal contraception or intrauterine device) in addition to condom plus spermicide, for four weeks before entering the trial, during the trial and for six months afterwards are considered eligible.

• Male patients with partners of child-bearing potential unless they agree to take measures not to father children by using one form of highly effective contraception including: oral, injected or implanted hormonal contraception or intra-uterine device in addition to condom plus spermicide, during the trial and for six months afterwards). Men with pregnant or lactating partners should be advised to use barrier method contraception (condom plus spermicidal gel) during the trial and for six months afterwards to prevent exposure to the foetus or neonate.

• Participants who have participated in another research trial involving an investigational product in the past 12 weeks.

• Severe immunologic defect or compromised bone marrow function.

• Patients who are serologically positive for Hepatitis B, Hepatitis C or HIV.

• Previous doxorubicin and epirubicin must not have exceeded 450 mg/m2 and 900 mg/m2, respectively.

• Patients who have a contraindication to MRI scans, for example patients who have a cardiac pacemaker, will be excluded from Arm B (as per Arm Assignment criteria, Appendix 3 of protocol).